594741 The disclosure relates to compositions, such as pharmaceutical compositions, comprising specific diarylhydantoin and diarylthiohydantoin compounds of formula (I) where X is S or O, and when X is S then R1 is OH or NH2 and when X is O then R1 is OH, NH2 or NHMe or salts or solvates thereof. Isolated and purified forms of the compounds are also described, as are unit dosage forms, compositions comprising substantially pure compound and kits comprising the compounds. The compounds and pharmaceutical compositions thereof may find use in the prevention and/or treatment of medical conditions, including prostate cancer, Parkinson&rsquos disease, Alzheimer&rsquos disease, and others. Compounds of the disclosure include: 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluorobenzoic acid 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluorobenzamide 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-2,4-dioxoimidazolidin-1-yl)-2-fluorobenzamide 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-2,4- dioxoimidazolidin-1-yl)-2-fluoro-N-methylbenzamide 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-2,4-dioxoimidazolidin-1-yl)-2-fluorobenzoic acid
